We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents with the potential to reach the market this year or early next year for resistant hypertension, myopia in children, and metachromatic leukodystrophy.
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- The new Centers for Disease Control and Prevention (CDC) recommendations for hepatitis B, summaries of drug shortages, and prescription to over-the-counter (OTC) switches.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
